Looking to take advantage of 'silenced' enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0
Gene therapy has made big strides over the years, from the first generation AAV-based therapies to the CRISPR/Cas9 technology that has now taken the scientific world — and Nobel Prize committee — by storm. But where exactly does the future, or gene therapy 3.0, lie?
That’s the question a new biotech is aiming to answer, as SalioGen Therapeutics emerges from stealth Monday morning with a $20 million Series A. And they believe they’ve found a new delivery system that can more precisely deliver genes in vivo than the relatively large adeno-associated virus or CRISPR system: mammalian-derived enzymes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
